Tanibirumab, a fully human anti-VEGFR2 monoclonal antibody
PharmAbcine Inc, California, United States
Recently, Tanibirumab has been successfully completed in Phase I study in Korea. Under the controlling of clinical CRO, twenty-six Korean cancer patients were enrolled and treated with Tanibirumab. Considering main purpose of Phase I trial is to assess safety profile, we can have final report with stable data of toxicity.
Primary Application Area: Biotech & Biological Sciences
Technology Development Status: Proven Manufacturability
Technology Readiness Level: TRL 6
FIGURES OF MERIT
Value Proposition: Tanibirumab patent is registered on Korea, China, Japan, Singapore, EP and will be registered on USA, Canada, and Australia within a few months. Generally, some side effects like hypertension and blood breeding were commonly found in VEGF/VEGFR-2 signal blockers but there was no sign like those in Tanibirumab.
Organization Type: Mid-stage Startup (A or B)
Showcase Booth #: 904
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: We have received around $ 7 M of government grant since the Company establishment. Here is the list below.
Primary Sources of Funding: Venture Capital
Looking for: Both Funding and Development Partners